| Literature DB >> 35081705 |
Sofia R Valdoleiros1, Cristina Torrão2, Laura S Freitas3, Diana Mano2, Celina Gonçalves2, Carla Teixeira2,4,5.
Abstract
BACKGROUND: Nosocomial meningitis is a medical emergency that requires early diagnosis, prompt initiation of therapy, and frequent admission to the intensive care unit (ICU).Entities:
Keywords: bacterial meningitis; central nervous system infections; critical care; critical illness; healthcare-associated meningitis; hospital infection
Year: 2022 PMID: 35081705 PMCID: PMC8918708 DOI: 10.4266/acc.2021.01151
Source DB: PubMed Journal: Acute Crit Care ISSN: 2586-6052
Figure 1.Flowchart of patients included in the study. ICU: intensive care unit.
Patients’ characteristics
| Demographics | Value |
|---|---|
| Age (yr) | 59±16 |
| Age ≥65 yr | 24 (34.3) |
| Male | 44 (62.9) |
| Functional status: independent | 64 (91.4) |
| Underlying disease | |
| Immunosuppressive therapy | 3 (4.3) |
| Primary immunodeficiency | 1 (1.4) |
| Diabetes mellitus | 9 (12.9) |
| Type 2, insulin-treated | 2 (2.9) |
| Type 2, non-insulin-treated | 7 (10.0) |
| Alcohol abuse | 13 (18.6) |
| Drug abuse | 1 (1.4) |
| Predisposing condition | N () |
| TBI | 24 (34.3) |
| Basal skull fracture | 7 (10.0) |
| CNS invasive procedure | 62 (88.6) |
| Craniotomy | 31 (44.3) |
| Craniectomy | 17 (24.3) |
| Cranioplasty | 1 (1.4) |
| Spinal surgery | 4 (5.7) |
| CNS invasive device | 45 (64.3) |
| EVD | 23 (32.8) |
| ICP-monitoring catheter | 32 (45.7) |
| Lumbar drain | 4 (5.7) |
| Distant focus of infection | 2 (2.9) |
| Odontogenic abscess | 1 (1.4) |
| Endocarditis | 1 (1.4) |
Values are presented as mean±standard deviation or number (%).
TBI: traumatic brain injury; CNS: central nervous system; EVD: external ventricular drain; ICP: intracranial pressure.
Clinical and laboratory characteristics of CNS infection
| Variable | Value |
|---|---|
| Sign and symptom | |
| Fever | 63 (90) |
| Nausea or vomiting | 4 (5.7) |
| Meningism | 3 (4.3) |
| Seizure | 11 (15.7) |
| Partial seizures | 6 (8.6) |
| Non-convulsive status epilepticus | 4 (5.7) |
| Generalized tonic-clonic seizures | 1 (1.4) |
| Non-sedated patient | 38 (54.3) |
| Headache | 3 (4.3) |
| Behavior change | 6 (8.6) |
| New focal deficits | 5 (7.1) |
| “AVPU” at diagnosis | |
| Alert | 11 (15.7) |
| Responsive to verbal stimuli | 4 (5.7) |
| Responsive to pain | 15 (21.4) |
| Unresponsive | 8 (11.4) |
| Glasgow coma score at diagnosis | |
| 3–8 points | 13 (18.6) |
| 9–13 points | 15 (21.4) |
| 14–15 points | 8 (11.4) |
| Timing of symptoms and diagnosis | |
| Time between hospital admission and diagnosis | 10.9±8.6 (1–48) |
| Time until readmission | 9.2±4.6 (2–13) |
| Time between any predisposing factor and signs/symptoms | 6.7±5.8 (0–25) |
| Time between TBI and signs/symptoms | 6.6±6.5 (2–34) |
| Time between basal skull fracture and signs/symptoms | 6.2±4.2 (2–12) |
| Time between CNS invasive procedure and signs/symptoms | 6.5±5.6 (0–25) |
| Time between CNS invasive device and signs/symptoms | 5.5±6.0 (0–41) |
| Time between symptoms and diagnosis | 2.0±2.1 (0–10) |
| Time between any predisposing factor and diagnosis | 9.0±7.5 (2–43) |
| Time between TBI and diagnosis | 8.9±6.5 (2–37) |
| Time between basal skull fracture and diagnosis | 7.3±4.2 (2–13) |
| Time between CNS invasive procedure and diagnosis | 8.7±6.1 (2–29) |
| Time between CNS invasive device and diagnosis | 7.4±6.2 (0–43) |
| Blood panel | |
| White cell count (/mm3) | 11,690±5,516 (980–27,660) |
| Neutrophils (/mm3) | 9,226±4,572 (630–22,740) |
| C-reactive protein (mg/L) | 127±93 (13–493) |
| Procalcitonin (ng/ml) | 0.24 (0.17–0.78) |
| Albumin (g/dl) | 2.9±0.46 (1.65–4.00) |
| CSF analysis | |
| Glucose (g/L) | 0.69±0.35 (0.01–1.45) |
| Protein (g/L) | 1.15 (0.65–1.84) |
| Red cell (/μl) | 24,300 (2,350–89,500) |
| White cell (/μl) | 359 (132–1,634) |
| Polymorphonuclear cell (/μl) | 255 (69–1,021) |
| Mononuclear cell (/μl) | 106 (31–294) |
Values are presented as number (%), mean±standard deviation (range), or median (interquartile range).
CNS: central nervous system; TBI: traumatic brain injury; CSF: cerebrospinal fluid.
Microbiological results
| Microbiologic result | No. (%) |
|---|---|
| Positive culture | 21 (30.0) |
| CSF | 9 (12.9) |
| Blood | 12 (17.1) |
| Other (CNS biopsy, exudate) | 5 (7.1) |
| Infectious agent | |
| | 2 (2.9) |
| | 1 (1.4) |
| | 1 (1.4) |
| | 1 (1.4) |
| | 1 (1.4) |
| | 2 (2.9) |
| | 1 (1.4) |
| | 1 (1.4) |
| | 4 (5.7) |
| | 3 (4.3) |
| | 1 (1.4) |
| | 2 (2.9) |
| | 2 (2.9) |
| | 3 (4.3) |
| Etiology | |
| Strictly bacterial | 18 (25.7) |
| Gram-negative bacterial infection | 11 (15.7) |
| Gram-positive bacterial infection | 6 (8.6) |
| Both (Gram-positive and Gram-negative) | 1 (1.4) |
| Fungal | 2 (2.9) |
| Mixed fungal and bacterial | 1 (1.4) |
CSF: cerebrospinal fluid; CNS: central nervous system.
Treatment
| Treatment | Value |
|---|---|
| Empirical antimicrobial therapy | |
| Ceftazidime plus vancomycin | 42 (60) |
| Meropenem plus vancomycin | 22 (31.4) |
| Route of therapy | |
| Intravenous only | 69 (98.6) |
| Intravenous and intraventricular | 1 (1.4) |
| Duration of antibiotic therapy (day)[ | 18.0±8.3 |
| Other therapeutic measure | |
| Corticoid | 13 (19.4) |
| Intracranial hypertension management | |
| Antiedematous therapy | 8 (11.4) |
| Barbiturate coma therapy | 2 (2.8) |
| CSF shunt | 11 (15.7) |
| Craniectomy | 2 (2.9) |
| Neurosurgery for infection control | 4 (5.7) |
| Removal of CNS device | 2 (2.9) |
| Closure of CSF fistula | 1 (1.4) |
Values are presented as number (%) or mean±standard deviation.
CSF: cerebrospinal fluid; CNS: central nervous system.
Exclusion of patients treated with <10 days of antibiotics.
Outcomes
| Complication | Value |
|---|---|
| Any | 33 (47.1) |
| Organ failure | |
| Respiratory failure | 37 (52.9) |
| Shock with vasopressor support | 21 (30) |
| Acute renal failure | 11 (15.7) |
| Hematologic dysfunction | 12 (17.1) |
| Hepatic dysfunction | 8 (11.4) |
| Intracranial hypertension | 14 (20) |
| Hydrocephalus | 6 (8.6) |
| Brain abscess | 2 (2.9) |
| Cerebral venous sinus thrombosis | 2 (2.9) |
| Cerebral vasculitis | 1 (1.4) |
| Amaurosis | 1 (1.4) |
| Glasgow coma score at discharge | |
| 3–8 Points | 4 (5.7) |
| 9–13 Points | 13 (18.6) |
| 14–15 Points | 35 (50.0) |
| Mortality | |
| Death during hospitalization | 15 (21.4) |
| Death during ICU | 10 (14.3) |
| Death within 30 days after admission | 15 (21.4) |
| Death during and after hospitalization | 26 (37.1) |
| Length of stay | |
| Hospital length of stay in days | 38 (30–46) |
| ICU length of stay in days | 18±12 (1–53) |
| Readmission | |
| Readmission | 5 (7.1) |
| Readmission related to CNS infection | 2 (2.9) |
Values are presented as number (%), median (interquartile range), or mean±standard deviation (range).
ICU: intensive care unit; CNS: central nervous system.
Univariate analysis
| Variable | Any complication | Non-alert at discharge[ | 30-Day mortality and hospital mortality | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | |
| Demographics and underlying disease | ||||||
| Age ≥65 yr | 0.71 (0.26–1.93) | 0.51 | 1.30 (0.28–5.73) | 0.71 | 8.89 (2.42–32.68) | 0.001 |
| Male | 1.06 (0.40–2.82) | 0.90 | 7.60 (0.89–64.62) | 0.04 | 0.86 (0.27–2.76) | 1 |
| Previous partially dependent | 0.53 (0.09–3.12) | 0.68 | 0.80 (0.69–0.91) | 1 | 9.64 (1.57–59.32) | 0.02 |
| Immunocompromised | 0.80 (0.29–2.19) | 0.67 | 1.98 (0.51–7.68) | 0.47 | 1.03 (0.31–3.46) | 1 |
| Clinical feature | ||||||
| Fever at diagnosis | 0.16 (0.01–1.1) | 0.06 | 1.28 (1.11–1.48) | 0.57 | 0.65 (0.11–3.74) | 0.64 |
| GCS at diagnosis <8 points[ | 0.68 (0.23–2.00) | 0.48 | 4.09 (0.83–20.14) | 0.71 | 0.94 (0.27–3.22) | 1 |
| New focal neurological deficit at diagnosis[ | 5.67 (0.56–57.23) | 0.16 | - | 0.08 | 3.94 (0.55–28.11) | 0.3 |
| Complication (any) | NA | NA | 0.45 (0.11–1.92) | 0.33 | 2.78 (0.83–9.24) | 0.09 |
| Hospital stay (mean) | 2 (–37 to 13) | 0.34 | 35 (–94 to 61) | 0.65 | 30.4 (12.7–48.05) | 0.05 |
| Laboratory findings | ||||||
| C-reactive protein ≥100 mg/L | 1.29 (0.50–3.31) | 0.60 | 1.00 (0.26–3.77) | 1 | 0.95 (0.30–2.99) | 0.93 |
| CSF white cell ≥100 per μl | 1.10 (0.33–3.61) | 0.88 | 3.12 (0.36–27.50) | 0.42 | 0.79 (0.18–3.40) | 0.71 |
| CSF glucose level <0.30 g/L | 0.99 (0.24–4.09) | 1 | 3.56 (0.66–19.11) | 0.15 | 1.31 (0.24–7.29) | 0.67 |
| CSF protein level ≥1 g/L | 1.52 (0.55–4.17) | 0.42 | 0.51 (0.13–1.96) | 0.49 | 1.42 (0.38–5.31) | 0.75 |
| Concomitant bacteremia | 1.15 (0.33–3.98) | 0.83 | 0.63 (0.07–5.88) | 1 | 3.43 (0.90–13.02) | 0.11 |
| Negative CSF culture | 0.56 (0.20–1.58) | 0.27 | 0.78 (0.18–3.52) | 0.71 | 0.27 (0.08–0.89) | 0.05 |
| Treatment | ||||||
| Meropenem plus vancomycin[ | 3.15 (1.08–9.22) | 0.03 | 0.96 (0.21–4.30) | 1 | 2.25 (0.63–8.06) | 0.31 |
| Antibiotic treatment >14 days[ | 2.84 (0.91–8.86) | 0.07 | 1.48 (0.29–7.54) | 0.70 | 1.05 (0.19–5.74) | 1 |
| Steroid therapy | 3.54 (0.97–12.96) | 0.05 | 4.34 (0.93–20.30) | 0.07 | 2.22 (0.56–8.82) | 0.26 |
| Antiedematous therapy (including barbiturates) | - | 0.001 | 1.41 (0.24–8.16) | 0.65 | - | 0.19 |
| CSF shunt | 1.42 (0.39–5.18) | 0.59 | 0.45 (0.05–4.04) | 0.67 | 0.79 (0.15–4.10) | 1 |
| Neurology consult | 0.92 (0.34–2.48) | 0.87 | 5.25 (1.29–21.40) | 0.03 | 1.37 (0.42–4.44) | 0.60 |
| Neurosurgery consult | 1.69 (0.45–6.40) | 0.44 | 1.58 (0.17–14.66) | 1 | 0.40 (0.10–1.61) | 0.23 |
OR: odds ratio; CI: confidence interval; GCS: Glasgow coma scale; NA: non-applicable CSF: cerebrospinal fluid.
Deceased patients excluded;
Sedated patients excluded;
Versus ceftazidime plus vancomycin;
Exclusion of patients treated with <10 days of antibiotics.
Multivariate analysis for 30-day mortality and hospital mortality
| Variable | OR (95% CI) | P-value |
|---|---|---|
| Age ≥65 yr | 10.08 (2.03–50.03) | 0.01 |
| Male | 1.15 (0.25–5.32) | 0.86 |
| Previous partially dependent | 4.45 (0.42–46.70) | 0.21 |
| Complications (any) | 5.04 (1.01–25.19) | 0.05 |
| Negative CSF culture | 0.53 (0.07–1.30) | 0.11 |
OR: odds ratio; CI: confidence interval; CSF: cerebrospinal fluid.